MARKET

CSTL

CSTL

Castle Biosciences
NASDAQ
24.30
+1.39
+6.07%
After Hours: 24.50 +0.2 +0.82% 19:51 06/26 EDT
OPEN
22.67
PREV CLOSE
22.91
HIGH
24.34
LOW
22.67
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
44.28
52 WEEK LOW
14.59
MARKET CAP
737.02M
P/E (TTM)
-56.5774
1D
5D
1M
3M
1Y
5Y
1D
Castle Biosciences’ i31-SLNB outperforms MIA nomogram in lymph node biopsy
TipRanks · 3d ago
Castle Biosciences Announces Published Study In 'Dermatology And Therapy' Showing DecisionDx-Melanoma Test Outperforms MIA Nomogram In Predicting Sentinel Lymph Node Positivity Risk
Benzinga · 3d ago
Castle Biosciences says DecisionDx-Melanoma i31-SLNB beats MIA nomogram in prospective SLNB risk study
PUBT · 3d ago
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
PR Newswire · 3d ago
This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Benzinga · 3d ago
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday
Benzinga · 3d ago
This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 3d ago
Castle Biosciences Initiated at Buy by Roth Capital
Dow Jones · 3d ago
More
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).

Webull offers Castle Biosciences Inc stock information, including NASDAQ: CSTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CSTL stock methods without spending real money on the virtual paper trading platform.